dc.contributor.author | Becherini, C | |
dc.contributor.author | Visani, L | |
dc.contributor.author | Caini, S | |
dc.contributor.author | Bhattacharya, IS | |
dc.contributor.author | Kirby, AM | |
dc.contributor.author | Nader Marta, G | |
dc.contributor.author | Morgan, G | |
dc.contributor.author | Salvestrini, V | |
dc.contributor.author | Coles, CE | |
dc.contributor.author | Cortes, J | |
dc.contributor.author | Curigliano, G | |
dc.contributor.author | de Azambuja, E | |
dc.contributor.author | Harbeck, N | |
dc.contributor.author | Isacke, CM | |
dc.contributor.author | Kaidar-Person, O | |
dc.contributor.author | Marangoni, E | |
dc.contributor.author | Offersen, B | |
dc.contributor.author | Rugo, HS | |
dc.contributor.author | Morandi, A | |
dc.contributor.author | Lambertini, M | |
dc.contributor.author | Poortmans, P | |
dc.contributor.author | Livi, L | |
dc.contributor.author | Meattini, I | |
dc.coverage.spatial | Netherlands | |
dc.date.accessioned | 2023-10-20T13:16:08Z | |
dc.date.available | 2023-10-20T13:16:08Z | |
dc.date.issued | 2023-09-01 | |
dc.identifier | ARTN 102586 | |
dc.identifier | S0305-7372(23)00078-6 | |
dc.identifier.citation | Cancer Treatment Reviews, 2023, 119 pp. 102586 - | |
dc.identifier.issn | 0305-7372 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6022 | |
dc.identifier.eissn | 1532-1967 | |
dc.identifier.eissn | 1532-1967 | |
dc.identifier.doi | 10.1016/j.ctrv.2023.102586 | |
dc.description.abstract | The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving survival outcomes compared to endocrine therapy alone. Abemaciclib and ribociclib, in combination with endocrine therapy, have demonstrated significant benefits in invasive disease-free survival for high-risk HR+/HER2- early breast cancer patients. Each CDK4/6i-palbociclib, ribociclib, and abemaciclib-exhibits distinct toxicity profiles. Radiation therapy (RT) can be delivered with a palliative or ablative intent, particularly using stereotactic body radiation therapy for oligometastatic or oligoprogressive disease. However, pivotal randomized trials lack information on concomitant CDK4/6i and RT, and existing preclinical and clinical data on the potential combined toxicities are limited and conflicting. As part of a broader effort to establish international consensus recommendations for integrating RT and targeted agents in breast cancer treatment, we conducted a systematic review and meta-analysis to evaluate the safety profile of combining CDK4/6i with palliative and ablative RT in both metastatic and early breast cancer settings. | |
dc.format | Print-Electronic | |
dc.format.extent | 102586 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCI LTD | |
dc.relation.ispartof | Cancer Treatment Reviews | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Breast cancer | |
dc.subject | CDK4/6 inhibitors | |
dc.subject | Meta-analysis | |
dc.subject | Radiotherapy | |
dc.subject | Systematic review | |
dc.subject | Toxicity | |
dc.subject | Humans | |
dc.subject | Female | |
dc.subject | Radiosurgery | |
dc.subject | Breast Neoplasms | |
dc.subject | Cyclin-Dependent Kinases | |
dc.subject | Cyclin-Dependent Kinase 4 | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Cyclin-Dependent Kinase 6 | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.title | Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-06-10 | |
dc.date.updated | 2023-10-19T15:19:57Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.ctrv.2023.102586 | |
rioxxterms.licenseref.startdate | 2023-09-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37336117 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Cell Biology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ctrv.2023.102586 | |
pubs.volume | 119 | |
icr.researchteam | Molecular Cell Biology | |
dc.contributor.icrauthor | Isacke, Clare | |
icr.provenance | Deposited by Ms Alex Carroll (impersonating Prof Clare Isacke) on 2023-10-19. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0305737223000786-main.pdf | |